IL25251A - Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation - Google Patents
Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparationInfo
- Publication number
- IL25251A IL25251A IL2525166A IL2525166A IL25251A IL 25251 A IL25251 A IL 25251A IL 2525166 A IL2525166 A IL 2525166A IL 2525166 A IL2525166 A IL 2525166A IL 25251 A IL25251 A IL 25251A
- Authority
- IL
- Israel
- Prior art keywords
- solution
- ophthalmic
- centipoises
- preparation
- dexamethasone phosphate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 36
- 238000000034 method Methods 0.000 title claims description 30
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 title claims description 28
- 239000004354 Hydroxyethyl cellulose Substances 0.000 title claims description 28
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 title claims description 28
- 238000002360 preparation method Methods 0.000 title claims description 18
- 239000000243 solution Substances 0.000 claims description 52
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 29
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 27
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 238000005352 clarification Methods 0.000 claims description 16
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 claims description 15
- 229960001963 pilocarpine nitrate Drugs 0.000 claims description 15
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 13
- 229940053050 neomycin sulfate Drugs 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- -1 hydroxy- Chemical class 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 claims description 4
- 229960004833 dexamethasone phosphate Drugs 0.000 claims description 4
- 238000001879 gelation Methods 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000000499 gel Substances 0.000 description 32
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 30
- 229960000380 propiolactone Drugs 0.000 description 28
- 239000004615 ingredient Substances 0.000 description 20
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 19
- 239000001509 sodium citrate Substances 0.000 description 19
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 15
- 229940109239 creatinine Drugs 0.000 description 15
- 239000000600 sorbitol Substances 0.000 description 15
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 13
- 229960000686 benzalkonium chloride Drugs 0.000 description 13
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 13
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 13
- 229960000654 sulfafurazole Drugs 0.000 description 13
- 239000008215 water for injection Substances 0.000 description 13
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 12
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 229960004926 chlorobutanol Drugs 0.000 description 5
- 229940060367 inert ingredients Drugs 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 229940001474 sodium thiosulfate Drugs 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003885 eye ointment Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229910052573 porcelain Inorganic materials 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 101150018711 AASS gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- MBMQMHMUOYKNBN-UHFFFAOYSA-K trisodium 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O MBMQMHMUOYKNBN-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47676865A | 1965-07-20 | 1965-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL25251A true IL25251A (en) | 1969-11-12 |
Family
ID=23893184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL2525166A IL25251A (en) | 1965-07-20 | 1966-02-24 | Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE678695A (enrdf_load_stackoverflow) |
| CH (1) | CH468190A (enrdf_load_stackoverflow) |
| DK (1) | DK115865B (enrdf_load_stackoverflow) |
| ES (1) | ES325333A1 (enrdf_load_stackoverflow) |
| FR (1) | FR6039M (enrdf_load_stackoverflow) |
| GB (1) | GB1090492A (enrdf_load_stackoverflow) |
| IL (1) | IL25251A (enrdf_load_stackoverflow) |
| NL (1) | NL6604206A (enrdf_load_stackoverflow) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179497A (en) | 1973-12-17 | 1979-12-18 | Merck & Co., Inc. | Solid state ophthalmic medication |
| US4045558A (en) * | 1975-10-08 | 1977-08-30 | Merck & Co., Inc. | Pilocarpine salts |
| US4131651A (en) | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) * | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| GB2169508B (en) * | 1985-01-11 | 1989-02-01 | Smith & Nephew Ass | Ophthalmic compositions and use |
| DE4020623C2 (de) * | 1990-06-29 | 1996-06-05 | Mezotraslevoj Nt Kompleks Mikr | Hornhaut-Protektor und Verfahren zu dessen Herstellung |
| WO2000019978A2 (en) | 1998-10-05 | 2000-04-13 | The Penn State Research Foundation | Compositions and methods for enhancing receptor-mediated cellular internalization |
| ITMI20122002A1 (it) * | 2012-11-26 | 2014-05-27 | Farmacologico Milanese Srl Lab | Preparazioni farmaceutiche liquide stabilizzate |
| AU2014209346B2 (en) | 2013-01-23 | 2018-11-15 | Semnur Pharmaceuticals, Inc. | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid |
| WO2014118051A1 (de) * | 2013-01-30 | 2014-08-07 | Sika Technology Ag | Erhärtungsbeschleuniger für mineralische bindemittel |
| TWI674899B (zh) | 2015-01-21 | 2019-10-21 | 美商桑紐爾製藥公司 | 醫藥配方 |
| DE102015226456A1 (de) * | 2015-12-22 | 2017-06-22 | Heraeus Medical Gmbh | Verfahren zur Sterilisation von wässrigen Polysaccharidlösungen und sterile wässrige Polysaccharidlösungen |
-
1966
- 1966-02-24 IL IL2525166A patent/IL25251A/en unknown
- 1966-03-02 GB GB914566A patent/GB1090492A/en not_active Expired
- 1966-03-29 CH CH453066A patent/CH468190A/de unknown
- 1966-03-30 ES ES0325333A patent/ES325333A1/es not_active Expired
- 1966-03-30 DK DK165166A patent/DK115865B/da unknown
- 1966-03-30 BE BE678695D patent/BE678695A/xx not_active IP Right Cessation
- 1966-03-30 NL NL6604206A patent/NL6604206A/xx unknown
- 1966-06-29 FR FR67423A patent/FR6039M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL6604206A (enrdf_load_stackoverflow) | 1967-01-23 |
| BE678695A (enrdf_load_stackoverflow) | 1966-09-30 |
| GB1090492A (en) | 1967-11-08 |
| DK115865B (da) | 1969-11-17 |
| FR6039M (enrdf_load_stackoverflow) | 1968-07-11 |
| CH468190A (de) | 1969-02-15 |
| ES325333A1 (es) | 1967-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL25251A (en) | Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation | |
| AU595240B2 (en) | Pharmaceutical composition of the type which undergoes liquid-gel phase transition | |
| US20080089918A1 (en) | Viscoelastic Solutions Containing Sodium Hyaluronate And Hydroxypropyl Methyl Cellulose, Preparation And Uses | |
| CA2251982C (en) | Ophthalmic compound with extended dwell time on the eye | |
| GB1571832A (en) | Medical dressings containing pharmaceutically active material | |
| US4087538A (en) | Ophthalmic suspensions | |
| JP2003528797A (ja) | ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物 | |
| EP0275457B1 (en) | Solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate | |
| NZ328774A (en) | Sterile ophthalmologic gel drop preparation and a process for producing it | |
| US3008875A (en) | Neomycin and mirystyl-gamma-picolinium halide compositions | |
| JPS58167509A (ja) | ゲル化ｐｇｅ↓２／トリアセチン溶液 | |
| GB2169508A (en) | Ophthalmic solutions containing hydroxyethyl cellulose | |
| JPH08295622A (ja) | 再分散性の優れたイオン性高分子配合水性懸濁点眼剤 | |
| JP3731894B2 (ja) | 滅菌プレドニソロンゲルの製造方法 | |
| EP0363502B1 (de) | Flüssiges, wismuthaltiges Arzneipräparat, Verfahren zum Herstellen desselben und seine Verwendung | |
| JPH06263629A (ja) | メスナ注射液、その製造方法およびそれからなる、オキシアザホスホリン副作用をさけるための医薬 | |
| AT269345B (de) | Verfahren zur Herstellung einer sterilen, von festen Teilchen freien Zubereitung für die Augenheilkunde | |
| GB1149648A (en) | Sterilisation of solids for use in aqueous suspensions | |
| CN1063944C (zh) | 眼用复方妥布霉素混悬液的制法 | |
| IT202200021852A1 (it) | Composizione liquida oftalmica viscosa comprendente gomme ed estratti naturali | |
| EP0770383B1 (en) | Ophthalmic cromolyn gel preparation | |
| CA1218675A (en) | Method for the preparation of p- butoxyphenylacetylhydroxamic acid in the finely divided state and a composition containing this acid | |
| US4093733A (en) | Parenteral suspensions | |
| JPS6067468A (ja) | 新規な注射用組成物 | |
| JPH05951A (ja) | コルチコステロイド含有水性懸濁点眼剤 |